• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Mereo BioPharma Group plc

    6/11/25 7:51:48 PM ET
    $MREO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MREO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Mereo BioPharma Group plc

    (Name of Issuer)


    Ordinary Shares, par value GBP 0.003 per share

    (Title of Class of Securities)


    589492107

    (CUSIP Number)


    06/04/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Northpond Ventures, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    35,223,695.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    35,223,695.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    35,223,695.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Northpond Ventures GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    35,223,695.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    35,223,695.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    35,223,695.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Northpond Ventures II, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    16,454,455.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    16,454,455.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,454,455.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Northpond Ventures II GP, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    16,454,455.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    16,454,455.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    16,454,455.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    2.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    NPV Listed, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,842,850.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,842,850.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,842,850.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Northpond Ventures, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,842,850.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,842,850.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,842,850.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.4 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    589492107


    1Names of Reporting Persons

    Michael P. Rubin
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    54,521,000.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    54,521,000.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    54,521,000.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Mereo BioPharma Group plc
    (b)Address of issuer's principal executive offices:

    4th Floor, One Cavendish Place, London, X0, W1G 0QF.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Northpond Ventures, LP ("Northpond Fund") Northpond Ventures GP, LLC ("Northpond GP LLC") Northpond Ventures II, LP ("Northpond Fund II") Northpond Ventures II GP, LLC ("Northpond GP II LLC") NPV Listed, LLC ("NPV Listed") Northpond Ventures, LLC ("Northpond Ventures") Michael P. Rubin ("Rubin") The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
    (b)Address or principal business office or, if none, residence:

    The principal business office of each Reporting Person is: 7500 Old Georgetown Road, Suite 800 Bethesda, MD 20814
    (c)Citizenship:

    Northpond Fund Delaware Northpond GP LLC Delaware Northpond Fund II Delaware Northpond GP II LLC Delaware NPV Listed Delaware Northpond Ventures Delaware Rubin United States
    (d)Title of class of securities:

    Ordinary Shares, par value GBP 0.003 per share
    (e)CUSIP No.:

    589492107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 589492107 has been assigned to the American Depositary Shares ("ADSs") of the Issuer. Each ADS represents five ordinary shares. Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) ordinary shares in the form of 7,044,739 ADSs directly held by Northpond Fund; (ii) ordinary shares in the form of 3,290,891 ADSs directly held by Northpond Fund II; (iii) ordinary shares in the form of 568,570 ADSs directly held by NPV Listed. Northpond GP LLC is the general partner of Northpond Fund, Northpond GP II LLC is the general partner of Northpond Fund II and Northpond Ventures is the manager of NPV Listed. Rubin is the managing member of each of Northpond GP LLC, Northpond GP II LLC and Northpond Ventures and has voting and dispositive power over the securities held by each of Northpond Fund, Northpond Fund II and NPV Listed.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentages of the shares of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is based upon upon 795,001,444 ordinary shares outstanding as of May 12, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 13, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Northpond Ventures, LP
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By: Northpond Ventures GP, LLC, its General Partner, By Patrick Smerkers, Authorized Signatory
    Date:06/11/2025
     
    Northpond Ventures GP, LLC
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By Patrick Smerkers, Authorized Signatory
    Date:06/11/2025
     
    Northpond Ventures II, LP
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By: Northpond Ventures II GP, LLC, its General Partner, By Patrick Smerkers, Authorized Signatory
    Date:06/11/2025
     
    Northpond Ventures II GP, LLC
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By Patrick Smerkers, Authorized Signatory
    Date:06/11/2025
     
    NPV Listed, LLC
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By Northpond Ventures, LLC, its Manager, By Patrick Smerkers, CFO, Partner
    Date:06/11/2025
     
    Northpond Ventures, LLC
     
    Signature:/s/ Patrick Smerkers
    Name/Title:By Patrick Smerkers, CFO, Partner
    Date:06/11/2025
     
    Michael P. Rubin
     
    Signature:/s/ Michael P. Rubin
    Name/Title:Michael P. Rubin
    Date:06/11/2025
    Exhibit Information

    Exhibit 99.1 Joint Filing Agreement

    Get the next $MREO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MREO

    DatePrice TargetRatingAnalyst
    3/27/2025$7.00Overweight
    Analyst
    12/6/2024$7.00Buy
    Jefferies
    6/13/2024$8.00Outperform
    Robert W. Baird
    10/13/2023$4.00Buy
    BTIG Research
    8/12/2022$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $MREO
    Financials

    Live finance-specific insights

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

      LONDON, May 15, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate highlights. The Company reported cash and cash equivalents of $48.7 million as of March 31, 2024 and continues to expect this to fund its operations into 2026. "2024 is off to an exciting start following the completion of enrollment by our partner Ultragenyx in both the Orbit and Cosmic studies of setrusumab in Osteogenesis Imperfecta (OI) along with the continued advancement of the pre-laun

      5/15/24 4:01:44 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Mereo BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Highlights

      Progress continues in Phase 3 Orbit study of setrusumab in osteogenesis imperfecta (OI) Cash of $62.5 million as of March 31, 2025, expected to fund operations into 2027 LONDON, May 13, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the first quarter ended March 31, 2025, and provided recent corporate highlights. "As we close out the first quarter of 2025, we continue to anticipate that this will be an important, milestone-rich year for Mereo. The Phase 3 Orbit study of setrusumab in osteogenesis imperfecta remains on track to read-

      5/13/25 7:30:05 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Reports Full Year 2024 Financial Results and Provides Corporate Highlights

      Orbit Phase 3 study of setrusumab in osteogenesis imperfecta progressing toward second interim analysis, expected mid-2025 Alvelestat granted Orphan Designation by the European Commission for treatment of Alpha-1 Antitrypsin Deficiency-associated Lung Disease (AATD-LD) Cash of $69.8 million as of December 31, 2024, expected to fund operations into 2027 LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the full year ended December 31, 2024, and provided recent corporate highlights. "2024 was a

      3/26/25 7:30:36 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Healthcare Conference

      LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Wednesday, March 12, 2025, at 8:40 am ET / 1:40 pm GMT. A live audio webcast of the fireside chat can be accessed through the Investors section of the Company's website at www.mereobiopharma.com/investors. An archived replay of the webcast will be available on the Company's website for two weeks following the live event. About Mereo Bi

      3/5/25 7:30:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Analyst initiated coverage on Mereo BioPharma with a new price target

      Analyst initiated coverage of Mereo BioPharma with a rating of Overweight and set a new price target of $7.00

      3/27/25 8:18:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies initiated coverage on Mereo BioPharma with a new price target

      Jefferies initiated coverage of Mereo BioPharma with a rating of Buy and set a new price target of $7.00

      12/6/24 7:56:53 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on Mereo BioPharma with a new price target

      Robert W. Baird initiated coverage of Mereo BioPharma with a rating of Outperform and set a new price target of $8.00

      6/13/24 7:11:27 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 4:18:45 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 3:30:42 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Mereo BioPharma Group plc

      SC 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      11/14/24 11:44:32 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Mereo BioPharma Group plc

      SCHEDULE 13G - Mereo BioPharma Group plc (0001719714) (Subject)

      6/11/25 7:51:48 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/15/25 10:46:23 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Mereo BioPharma Group plc

      SCHEDULE 13G/A - Mereo BioPharma Group plc (0001719714) (Subject)

      5/14/25 4:34:46 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MREO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $MREO
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form 4 filed by Director Yoskowitz Marc J

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:22 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Bender Jeremy

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:14 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Shames Daniel

      4 - Mereo BioPharma Group plc (0001719714) (Issuer)

      2/6/25 4:30:06 PM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Dr. Abdul Mullick to Board of Directors

      LONDON and REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO) ("Mereo" or the "Company"), a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Dr. Abdul Mullick to the Company's Board of Directors, effective immediately. Dr. Mullick joins Mereo's Board with over 20 years of experience in the pharmaceutical industry in senior leadership positions across multiple therapeutic areas and geographies, including in rare diseases. "We are very excited to welcome Abdul to the Board at such a pivotal time for the Company," said Dr. Denise Scots-Knight, Chief Executive Officer of Mereo. "His e

      5/17/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Anne Hyland to Board of Directors

      LONDON and REDWOOD CITY, Calif., March 01, 2022 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Anne Hyland to the Company's Board of Directors, effective immediately. Ms. Hyland has also been appointed to serve on the Audit and Risk Committee of the Board. Ms. Hyland joins Mereo's Board with over 30 years of financial experience in both private and public companies in the biopharmaceutical space. "We are very excited to welcome someone with Anne's level of operational and board experience to our Board," said Dr. Denise Scots-Knight, C

      3/1/22 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mereo BioPharma Announces Appointment of Pierre Jacquet, M.D., Ph.D. to Board of Directors

      LONDON and REDWOOD CITY, Calif., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ:MREO), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, today announced the appointment of Pierre Jacquet, M.D., Ph.D to the Company's Board of Directors, effective September 20, 2021. Dr. Jacquet joins Mereo's Board with over two decades of multidisciplinary experience in the life science industry, including corporate strategy, M&A advisory and value management. "We are delighted to have Pierre joining our board of directors at such an exciting and important time for the Company," said Dr. Denise Scots-Knight, Chief Executive Off

      9/20/21 8:00:00 AM ET
      $MREO
      Biotechnology: Pharmaceutical Preparations
      Health Care